NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

LENZ Therapeutics, Inc. (LENZ) Stock Analysis

LENZ Therapeutics, Inc. (LENZ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LENZ

$3.22

+$0.03 (+0.94%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LENZ with… →

LENZ Key Statistics

As of Oct 21, 2026
Trading
Open
$3.20
Previous Close
$3.19
Day's Range
3.17–3.37
52-Week Range
3.12–34.27
Volume
943.34K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.73
Valuation
Market Cap
$101.17M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.71
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.13
Financials (FY)
Revenue (FY)
$19.09M
Net Income (FY)
−$82.13M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.42M
1-Year Return
−90.41%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
764.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LENZ closed at $3.22, −90.41% over 1 year.

LENZ Therapeutics, Inc. (LENZ) has a market capitalization of $101.17M.

In fiscal 2025, LENZ reported revenue of $19.09M.

LENZ Stock Return by Calendar Year

LENZ Therapeutics, Inc. (LENZ) return since Jun 2021: what $10,000 became

1 year
$10,000 $959
−90.41%
5 years
$10,000 $762
−92.38%
Since Jun 2021
$10,000 $522
−94.78%

If you had invested $10,000 in LENZ Therapeutics, Inc. (LENZ) at the close on June 25, 2021, the earliest close on record here, it would have been worth $522 at the close on October 21, 2026: −94.78% in total, −42.57% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−79.88%
2025−44.58%
2024+230.71%
2023−21.08%
2022−73.29%
2021 (partial year)−32.81%

As of October 21, 2026.

LENZ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$19.09M−$82.13M−430.3%
2024$0.00−$49.77M—
2023$0.00−$69.97M—
2022$15.00M−$10.81M−72.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$19.09M$18.67M−$91.14M−$82.13M−430.3%
2024$0.00$0.00−$58.61M−$49.77M—
2023$0.00—−$72.43M−$69.97M—
2022$15.00M—−$10.48M−$10.81M−72.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LENZ Valuation vs Biotechnology Median

Median of 608 stocks
MetricLENZBiotechnology medianvs median
P/S ratio4.7113.3065% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values LENZ Therapeutics, Inc. (LENZ) at $101.17M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 152 employees.

LENZ last closed at $3.22 on October 21, 2026. That is +$0.03 (+0.94%) against the previous close. The 52-week range on file runs from $3.12 to $34.27. The latest close sits 3.21% above that 52-week low.

Financial Health

In fiscal 2025, LENZ Therapeutics, Inc. reported revenue of $19.09M. The same year closed with a net loss of $82.13M. Earnings per share on a trailing basis come to −4.13.

Across the 4 fiscal years on file, revenue moves from $15.00M in 2022 to $19.09M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 4.71. On price-to-sales that is 64.57% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −90.41%. Measured over 5 years, that is −40.25% a year compounded. The reported beta is 1.73. Daily returns over the trailing 5 years annualize to a volatility of 75.35%.

Growth & Income

The latest dividend on file for LENZ dates from 2024.

So far in 2026 the total return is −79.88%. Across the complete calendar years on file, 2024 returned +230.71% and 2022 returned −73.29%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

LENZ Therapeutics, Inc. (LENZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
LENZ Therapeutics, Inc. LENZ $101.17M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. LENZ Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Visit website →